Seminars in Oncology
Volume 34, Issue 4 , Pages 327-334 , August 2007

Locally Advanced Pancreatic Cancer: A Review

  • Suzanne Russo

      Affiliations

    • Baptist Centers for Cancer Care, Memphis, TN.
    • ,
  • Jerome Butler

      Affiliations

    • Wake Forest University School of Medicine, Winston-Salem, NC.
    • ,
  • Roger Ove

      Affiliations

    • Baptist Centers for Cancer Care, Memphis, TN.
    • ,
  • A. William Blackstock

      Affiliations

    • Wake Forest University School of Medicine, Winston-Salem, NC.
    • Corresponding Author InformationAddress correspondence to A. William Blackstock, MD, Department of Radiation Oncology, Wake Forest University, Winston-Salem, NC 27157.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66
  2. Evans D, Abbruzzese J, Willett C. Cancer of the Pancreas. Philadelphia: Lippincott Williams & Wilkins; 2001;
  3. Americna Joint Committee on Cancer. In: Exocrine pancreas, in Cancer Staging Manual. New York: Springer; 2002;p. 157–164
  4. Fuhrman GM, Charnsangavej C, Abbruzzese JL, et al. Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. Am J Surg. 1994;167:104–111
  5. Diehl SJ, Lehmann KJ, Sadick M, et al. Pancreatic cancer: Value of dual-phase helical CT in assessing resectability. Radiology. 1998;206:373–378
  6. Lu DS, Reber HA, Krasny RM, et al. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR Am J Roentgenol. 1997;168:1439–1443
  7. Ichikawa T, Haradome H, Hachiya J, et al. Pancreatic ductal adenocarcinoma: preoperative assessment with helical CT versus dynamic MR imaging. Radiology. 1997;202:655–662
  8. Sheridan MB, Ward J, Guthrie JA, et al. Dynamic contrast-enhanced MR imaging and dual-phase helical CT in the preoperative assessment of suspected pancreatic cancer: A comparative study with receiver operating characteristic analysis. AJR Am J Roentgenol. 1999;173:583–590
  9. Schwarz M, Pauls S, Sokiranski R, et al. Is a preoperative multidiagnostic approach to predict surgical resectability of periampullary tumors still effective?. Am J Surg. 2001;182:243–249
  10. Eloubeidi MA, Jhala D, Chhieng DC, et al. Yield of endoscopic ultrasound-guided fine-needle aspiration biopsy in patients with suspected pancreatic carcinoma. Cancer. 2003;99:285–292
  11. Varadarajulu S, Eloubeidi MA. The role of endoscopic ultrasonography in the evaluation of pancreatico-biliary cancer. Gastrointest Endosc Clin N Am. 2005;15:497–511
  12. Orlando LA, Kulasingam SL, Matchar DB. Meta-analysis: The detection of pancreatic malignancy with positron emission tomography. Aliment Pharmacol Ther. 2004;20:1063–1070
  13. Stefanidis D, Grove KD, Schwesinger WH, et al. The current role of staging laparoscopy for adenocarcinoma of the pancreas: A review. Ann Oncol. 2006;17:189–199
  14. Jimenez RE, Warshaw AL, Rattner DW, et al. Impact of laparoscopic staging in the treatment of pancreatic cancer. Arch Surg. 2000;135:409–414
  15. Nieveen van Dijkum EJ, de Wit LT, van Delden OM, et al. Staging laparoscopy and laparoscopic ultrasonography in more than 400 patients with upper gastrointestinal carcinoma. J Am Coll Surg. 1999;189:459–465
  16. Minsky BD, Hilaris B, Fuks Z. The role of radiation therapy in the control of pain from pancreatic carcinoma. J Pain Symptom Manage. 1988;3:199–205
  17. Roldan GE, Gunderson LL, Nagorney DM, et al. External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer. Cancer. 1988;61:1110–1116
  18. Moertel CG, Childs DS, Reitemeier RJ, et al. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet. 1969;2:865–867
  19. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer. 1981;48:1705–1710
  20. Gastrointestinal Tumor Study Group. Radiation therapy combined with Adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Cancer. 1985;56:2563–2568
  21. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: A comparison of combined modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst. 1988;80:751–755
  22. Klassen D, MacIntyre J, GE C, et al. An Eastern Cooperative Oncology Group study Treatment of locally unresectable cancer of the stomach and pancreas: A randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil—. J Clin Oncol. 1985;3:373–378
  23. O’Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med. 1994;331:502–507
  24. Whittington R, Neuberg D, Tester WJ, et al. Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: A phase I Eastern Cooperative Oncology Group trial. J Clin Oncol. 1995;13:227–232
  25. Poen JC, Collins HL, Niederhuber JE, et al. Chemo-radiotherapy for localized pancreatic cancer: Increased dose intensity and reduced acute toxicity with concomitant radiotherapy and protracted venous infusion 5-fluorouracil. Int J Radiat Oncol Biol Phys. 1998;40:93–99
  26. Ben-Josef E, Shields AF, Vaishampayan U, et al. Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. Int J Radiat Oncol Biol Phys. 2004;59:454–459
  27. Saif MW, Eloubeidi MA, Russo S, et al. Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: Expression analysis of genes related to outcome. J Clin Oncol. 2005;23:8679–8687
  28. Schneider BJ, Ben-Josef E, McGinn CJ, et al. Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2005;63:1325–1330
  29. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol. 1997;15:2403–2413
  30. Fields MT, Eisbruch A, Normolle D, et al. Radiosensitization produced in vivo by once- vs. twice-weekly 2′2′-difluoro-2′-deoxycytidine (gemcitabine). Int J Radiat Oncol Biol Phys. 2000;47:785–791
  31. Lawrence TS, Chang EY, Hahn TM, et al. Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine. Int J Radiat Oncol Biol Phys. 1996;34:867–872
  32. Milas L, Fujii T, Hunter N, et al. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res. 1999;59:107–114
  33. Poggi MM, Kroog GS, Russo A, et al. Phase I study of weekly gemcitabine as a radiation sensitizer for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2002;54:670–676
  34. Ikeda M, Okada S, Tokuuye K, et al. A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Br J Cancer. 2002;86:1551–1554
  35. Blackstock AW, Bernard SA, Richards F, et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol. 1999;17:2208–2212
  36. Pipas JM, Mitchell SE, Barth RJ, et al. Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys. 2001;50:1317–1322
  37. Blackstock AW, Tepper JE, Niedwiecki D, et al. Cancer and Leukemia Group B (CALGB) 89805: Phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer. 2003;34:107–116
  38. Mishra G, Butler J, Ho C, et al. Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer. Am J Clin Oncol. 2005;28:345–350
  39. McGinn CJ, Zalupski MM, Shureiqi I, et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2001;19:4202–4208
  40. Crane CH, Janjan NA, Evans DB, et al. Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Pancreatol. 2001;29:9–18
  41. Wolff RA, Evans DB, Gravel DM, et al. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res. 2001;7:2246–2253
  42. Okusaka T, Ito Y, Ueno H, et al. Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. Br J Cancer. 2004;91:673–677
  43. Epelbaum R, Rosenblatt E, Nasrallah S, et al. Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer. J Surg Oncol. 2002;81:138–143
  44. Crane CH, Abbruzzese JL, Evans DB, et al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?. Int J Radiat Oncol Biol Phys. 2002;52:1293–1302
  45. Li CP, Chao Y, Chi KH, et al. Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys. 2003;57:98–104
  46. Talamonti MS, Catalano PJ, Vaughn DJ, et al. Eastern Cooperative Oncology Group phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: A regimen with unexpected early toxicity. J Clin Oncol. 2000;18:3384–3389
  47. Willett CG, Czito BG, Bendell JC, et al. Locally advanced pancreatic cancer. J Clin Oncol. 2005;23:4538–4544
  48. Safran H, Dipetrillo T, Iannitti D, et al. Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: A phase I trial. Int J Radiat Oncol Biol Phys. 2002;54:137–141
  49. Rich T, Harris J, Abrams R, et al. Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12. Am J Clin Oncol. 2004;27:51–56
  50. Ashamalla H, Zaki B, Mokhtar B, et al. Hyperfractionated radiotherapy and paclitaxel for locally advanced/unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2003;55:679–687
  51. Viret F, Ychou M, Goncalves A, et al. Docetaxel and radiotherapy and pancreatic cancer. Pancreas. 2003;27:214–219
  52. Shipley WU, Nardi GL, Cohen AM, et al. Iodine-125 implant and external beam irradiation in patients with localized pancreatic carcinoma: A comparative study to surgical resection. Cancer. 1980;45:709–714
  53. Syed AM, Puthawala AA, Neblett DL. Interstitial iodine-125 implant in the management of unresectable pancreatic carcinoma. Cancer. 1983;52:808–813
  54. Shipley WU, Wood WC, Tepper JE, et al. Intraoperative electron beam irradiation for patients with unresectable pancreatic carcinoma. Ann Surg. 1984;200:289–296
  55. Wood WC, Shipley WU, Gunderson LL, et al. Intraoperative irradiation for unresectable pancreatic carcinoma. Cancer. 1982;49:1272–1275
  56. Tepper JE, Shipley WU, Warshaw AL, et al. The role of misonidazole combined with intraoperative radiation therapy in the treatment of pancreatic carcinoma. J Clin Oncol. 1987;5:579–584
  57. Garton GR, Gunderson LL, Nagorney DM, et al. High-dose preoperative external beam and intraoperative irradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 1993;27:1153–1157
  58. Sindelar WF, Kinsella TJ. Studies of intraoperative radiotherapy in carcinoma of the pancreas. Ann Oncol. 1999;10(suppl 4):226–230
  59. Tepper JE, Noyes D, Krall JM, et al. Radiation Therapy Oncology Group Intraoperative radiation therapy of pancreatic carcinoma: A report of RTOG-8505. Int J Radiat Oncol Biol Phys. 1991;21:1145–1149
  60. Willett CG, Del Castillo CF, Shih HA, et al. Long-term results of intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancer. Ann Surg. 2005;241:295–299
  61. Dobelbower RR, Merrick HW, Ahuja RK, et al. 125I interstitial implant, precision high-dose external beam therapy, and 5-FU for unresectable adenocarcinoma of pancreas and extrahepatic biliary tree. Cancer. 1986;58:2185–2195
  62. Mohiuddin M, Cantor RJ, Biermann W, et al. Combined modality treatment of localized unresectable adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys. 1988;14:79–84
  63. Peretz T, Nori D, Hilaris B, et al. Treatment of primary unresectable carcinoma of the pancreas with I-125 implantation. Int J Radiat Oncol Biol Phys. 1989;17:931–935
  64. Smith FP, Schein PS, Macdonald JS, et al. Fast neutron irradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 1981;7:1527–1531
  65. Al-Abdulla AS, Hussey DH, Olson MH, et al. Experience with fast neutron therapy for unresectable carcinoma of the pancreas. Int J Radiat Oncol Biol Phys. 1981;7:165–172
  66. Cohen L, Woodruff KH, Hendrickson FR, et al. Response of pancreatic cancer to local irradiation with high-energy neutrons. Cancer. 1985;56:1235–1241
  67. Thomas FJ, Krall J, Hendrickson F, et al. Evaluation of neutron irradiation of pancreatic cancer (Results of a randomized Radiation Therapy Oncology Group clinical trial). Am J Clin Oncol. 1989;12:283–289
  68. Linstadt D, Quivey JM, Castro JR, et al. Comparison of helium-ion radiation therapy and split-course megavoltage irradiation for unresectable adenocarcinoma of the pancreas (Final report of a Northern California Oncology Group randomized prospective clinical trial). Radiology. 1988;168:261–264
  69. Crane CH, Antolak JA, Rosen II, et al. Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head. Int J Gastrointest Cancer. 2001;30:123–132
  70. Milano MT, Chmura SJ, Garofalo MC, et al. Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: Toxicity and clinical outcome. Int J Radiat Oncol Biol Phys. 2004;59:445–453
  71. Landry JC, Yang GY, Ting JY, et al. Treatment of pancreatic cancer tumors with intensity-modulated radiation therapy (IMRT) using the volume at risk approach (VARA): Employing dose-volume histogram (DVH) and normal tissue complication probability (NTCP) to evaluate small bowel toxicity. Med Dosim. 2002;27:121–129
  72. Koong AC, Christofferson E, Le QT, et al. Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2005;63:320–323
  73. Hoyer M, Roed H, Sengelov L, et al. Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol. 2005;76:48–53
  74. Crane C, Ellis L, Abbruzzese J, et al. Phase I trial of bevucizumab (BV) with concurrent radiotherapy (RT) and capecitabine (CAP) in locally advanced pancreatic adenocarcinoma (PA). Proc Am Soc Clin Oncol. 2005;23:316S;(abstr)
  75. Xiong HQ, Abbruzzese JL. Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol. 2002;29:31–37
  76. Abbruzzese J, Rosenberg A, Xiong Q, et al. Phase II study of an anti-epidermal growth factor receptor cetuximab (IM-C225) in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol. 2001;20:130a;(abstr)
  77. Safron H, Ramanathan R, Schwartz J, et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Proc Am Soc Clin Oncol. 2001;20:130;(abstr)
  78. Moore M, Goldstein D, Hamm J, et al: Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). ASCO Gastrointestinal Cancer Symposium. Miami, FL, January 27-29, 2005 (abstr 77)
  79. Kormansky J, O’Reilly E, Minsky B, et al: A phase I trial of erlotinib, gemcitabine and radiation for patients with locally-advanced, unresectable pancreatic cancer. ASCO Gastrointestinal Cancer Symposium. Miami, FL, January 27-29, 2005 (abstr 133)
  80. Iannitti D, Dipetrillo T, Akerman P, et al. Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: A phase I study. Am J Clin Oncol. 2005;28:570–575

PII: S0093-7754(07)00102-9

doi: 10.1053/j.seminoncol.2007.05.007

Seminars in Oncology
Volume 34, Issue 4 , Pages 327-334 , August 2007

Article Tools

* Image Usage & Resolution